This Article Full Text Full Text (PDF) All Versions of this Article: 48/6/1160    most recent 01.HYP.0000248129.20524.d0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fedorova, O. V. Articles by Bagrov, A. Y. Search for Related Content PubMed PubMed Citation Articles by Fedorova, O. V. Articles by Bagrov, A. Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Cardio-renal physiology/pathophysiology Hypertension - basic studies Peripheral vascular disease Related Article

(Hypertension. 2006;48:1160.)
© 2006 American Heart Association, Inc.

Original Articles

ANP Differentially Modulates Marinobufagenin-Induced Sodium Pump Inhibition in Kidney and Aorta

Olga V. Fedorova; Natalia I. Agalakova; Christopher H. Morrell; Edward G. Lakatta; Alexei Y. Bagrov

From the Laboratory of Cardiovascular Science (O.V.F., N.I.A., C.H.M., E.G.L., A.Y.B.), National Institute on Aging, National Institutes of Health, Baltimore, Md; and Loyola College in Maryland (C.H.M.), Baltimore.

Correspondence to Alexei Bagrov, Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Dr, Baltimore, MD 21224. E-mail BagrovA{at}mail.nih.gov

NaCl loading and plasma volume expansion stimulate 2 natriuretic systems, vasoconstrictor, digitalis-like Na/K-ATPase inhibitors and vasorelaxant ANP peptides. Several hormones, including ANP, regulate activity of the Na/K-ATPase by modulation of its phosphorylation state. We studied effects of ANP on Na/K-ATPase phosphorylation and inhibition by an endogenous sodium pump ligand, marinobufagenin, in the aorta and renal medulla from male Sprague–Dawley rats. Marinobufagenin dose-dependently inhibited the Na/K-ATPase in renal and vascular membranes at the level of higher (nanomolar) and lower affinity (micromolar) binding sites. Marinobufagenin (1 nmol/L) inhibited Na/K-ATPase in aortic sarcolemma (18%) and in renal medulla (19%). prepro-ANP 104 to 123 (ppANP) and -human ANP ([-hANP] both 1 nmol/L) potentiated marinobufagenin-induced Na/K-ATPase inhibition in the kidney, but reversed the effect of marinobufagenin in the aorta. Similarly, ppANP and -hANP modulated the sodium pump (ouabain-sensitive ⁸⁶Rb uptake) inhibitory effects of marinobufagenin in the aorta and renal medulla. In renal medulla, ppANP and -hANP induced -1 Na/K-ATPase phosphorylation, whereas in aorta, both peptides dephosphorylated Na/K-ATPase. The effect of ppANP on Na/K-ATPase phosphorylation and inhibition was mimicked by a protein kinase G activator, 8-Br-PET-cGMP (10 µmol/L), and prevented by a protein kinase G inhibitor, KT5823 (60 nmol/L). Our results suggest that -1 Na/K-ATPase inhibition by marinobufagenin in the kidney is enhanced via Na/K-ATPase phosphorylation by ANP, whereas in the aorta, ANP exerts an opposite effect. The concurrent production of a vasorelaxant, ANP, and a vasoconstrictor, marinobufagenin, potentiate each other’s natriuretic effects, but ANP peptides may offset the deleterious vasoconstrictor effect of marinobufagenin.

Key Words: sodium-potassium exchanging adenosinetriphosphatase • natriuretic hormones • ANP • ouabain • marinobufagenin • cGMP

Related Article:

Atrial Peptides Modify the Effect of Marinobufagenin on Sodium Pumps: Implications for Blood Pressure Control

Vardaman M. Buckalew
Hypertension 2006 48: 1029-1030. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				L. V. Fedorova, V. Raju, N. El-Okdi, A. Shidyak, D. J. Kennedy, S. Vetteth, D. R. Giovannucci, A. Y. Bagrov, O. V. Fedorova, J. I. Shapiro, et al. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition Am J Physiol Renal Physiol, April 1, 2009; 296(4): F922 - F934. [Abstract] [Full Text] [PDF]

				A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38. [Abstract] [Full Text] [PDF]

				E. L. Loreaux, B. Kaul, J. N. Lorenz, and J. B. Lingrel Ouabain-Sensitive {alpha}1 Na,K-ATPase Enhances Natriuretic Response to Saline Load J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1947 - 1954. [Abstract] [Full Text] [PDF]

				W. Schoner and G. Scheiner-Bobis Role of endogenous cardiotonic steroids in sodium homeostasis Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2723 - 2729. [Full Text] [PDF]

				D. E. Anderson, O. V. Fedorova, C. H. Morrell, D. L. Longo, V. A. Kashkin, J. D. Metzler, A. Y. Bagrov, and E. G. Lakatta Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1248 - R1254. [Abstract] [Full Text] [PDF]

				W. Schoner and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol, August 1, 2007; 293(2): C509 - C536. [Abstract] [Full Text] [PDF]

				V. M. Buckalew Atrial Peptides Modify the Effect of Marinobufagenin on Sodium Pumps: Implications for Blood Pressure Control Hypertension, December 1, 2006; 48(6): 1029 - 1030. [Full Text] [PDF]